Financial Performance - The company's revenue for Q3 2022 reached ¥879,765,668.34, representing a 31.67% increase year-over-year[4] - Net profit attributable to shareholders was ¥354,994,024.19, up 49.72% compared to the same period last year[4] - The basic earnings per share (EPS) was ¥0.4516, reflecting a 49.59% increase year-over-year[4] - The total operating revenue for the first three quarters was ¥229,667.69 million, a growth of 21.27% compared to the same period last year[13] - The net profit attributable to shareholders was ¥92,457.10 million, reflecting a year-on-year increase of 38.88%[13] - The company's operating profit for Q3 2022 was approximately CNY 1,060.96 million, an increase from CNY 771.30 million in the same period last year, representing a growth of about 37.5%[19] - Net profit for Q3 2022 reached CNY 924.57 million, compared to CNY 665.72 million in Q3 2021, marking an increase of approximately 38.9%[19] Research and Development - Research and development expenses increased by 56.34% to ¥223,451,384.74, indicating a significant investment in innovation[9] - Research and development expenses for the quarter were CNY 223.45 million, up from CNY 142.93 million in the previous year, indicating a year-over-year increase of about 56.2%[19] - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the provided data[18] - Future outlook includes continued investment in research and development to drive growth and innovation in the biomedical sector[18] - Research and development efforts are focused on innovative biomedical technologies to enhance product offerings and market competitiveness[43] Cash Flow and Assets - Cash flow from operating activities was ¥667,546,747.73, marking a 48.10% increase compared to the previous year[4] - The net cash flow from operating activities for the current period was ¥667,546,747.73, an increase of 48.10% compared to the previous period, primarily due to increased sales receipts and VAT refunds[10] - The net cash flow from investing activities was ¥279,832,591.36, a significant change of -185.62% from the previous period, attributed to differences in the duration of purchased financial products[10] - The net cash flow from financing activities was -¥500,718,900.07, reflecting a 76.02% increase in outflows due to the repurchase of restricted stock[10] - Cash and cash equivalents as of September 30, 2022, amounted to ¥1,039,272,293.16, compared to ¥617,579,779.05 at the beginning of the year[14] - The company reported cash and cash equivalents at the end of the period amounting to CNY 1,033.68 million, up from CNY 902.31 million at the end of the previous year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,661,803,096.06, an 8.58% increase from the previous year[4] - Total assets amounted to CNY 6,661,803,096.06, compared to CNY 6,135,507,556.27 at the beginning of the year, marking an increase of 8.6%[16] - Total liabilities were CNY 544,636,136.45, slightly up from CNY 523,508,864.94, reflecting a growth of 4.3%[17] - Owner's equity totaled CNY 6,117,166,959.61, an increase from CNY 5,611,998,691.33, showing a rise of 9.0%[17] Sales and Market Presence - The total number of automatic chemiluminescence analyzers sold/installed reached 4,778 units, a year-on-year increase of 35.47%[13] - The domestic business revenue in Q3 grew by 35.32% year-on-year, while overseas business revenue increased by 23.14%[13] - The number of terminal customers served in the domestic market exceeded 8,457, with 1,329 being tertiary hospitals, resulting in a coverage rate of 53.97%[13] - The revenue from overseas business in Q3 2022 increased by 23.14% year-on-year, with a 32.50% increase when excluding the impact of COVID-19 reagents[38] Profitability Metrics - The weighted average return on equity rose to 6.00%, an increase of 1.46 percentage points year-over-year[4] - The gross profit margin for instrument products was 22.29%, an increase of 7.02 percentage points year-over-year[13] - The company reported a net profit margin improvement, with net profit increasing significantly year-over-year, although specific figures were not disclosed in the provided data[18] - The total comprehensive income for Q3 2022 was CNY 937.84 million, compared to CNY 665.59 million in the same quarter last year, reflecting a growth of approximately 40.8%[20]

Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.2 billion for the first half of 2022, representing a year-on-year growth of 25%[6]. - The company's operating revenue for the reporting period was ¥1,416,911,249.55, representing a 15.60% increase compared to ¥1,225,706,671.90 in the same period last year[11]. - Net profit attributable to shareholders was ¥569,577,003.52, a 32.89% increase from ¥428,611,762.39 year-on-year[11]. - The net profit after deducting non-recurring gains and losses was ¥523,257,138.03, up 36.59% from ¥383,099,889.21 in the previous year[11]. - The total profit reached 652.91 million yuan, marking a year-on-year growth of 32.23%[31]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan for the first half of 2022, representing a year-over-year growth of 25%[80]. - The company provided a positive outlook for the second half of 2022, projecting a revenue growth of 20% to 25%[80]. - The company reported a total comprehensive income of CNY 569,354,332.94 for the first half of 2022, compared to CNY 428,457,184.67 in the previous year, indicating a growth of about 33%[129]. Market Expansion and Strategy - User data indicates that the company has expanded its customer base, with over 5,000 new clients acquired in the first half of 2022, marking a 15% increase compared to the previous period[6]. - The company is actively pursuing market expansion, with plans to enter two new international markets by Q4 2022, aiming for a 10% increase in overseas sales[6]. - The company plans to establish nine overseas subsidiaries, including in the Philippines and Pakistan, to enhance support and investment in key market countries[30]. - Market expansion plans include entering three new international markets by the end of 2022, targeting a 10% market share in each[80]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the biotech sector[80]. - The company is exploring potential mergers and acquisitions to enhance its market position, with a target of completing at least one acquisition by the end of 2022[6]. Research and Development - The company has allocated RMB 150 million for research and development in new technologies, focusing on enhancing the accuracy of diagnostic tests[6]. - The company invested ¥132,408,236.02 in R&D, marking a 55.86% increase year-on-year, reflecting a commitment to innovation[48]. - The company is investing heavily in R&D, with a budget increase of 15% for new technology development in 2022[80]. - The company has developed four major technology platforms for in vitro diagnostic products, enhancing its competitive edge in the market[29]. - The company is focusing on expanding its product line in the infectious disease segment, with multiple new products in various stages of development and clinical evaluation[35]. Financial Position - The company has maintained a strong cash position, with cash and cash equivalents totaling RMB 500 million as of June 30, 2022[6]. - The company's total assets at the end of the reporting period were ¥6,266,547,552.05, a 2.14% increase from ¥6,135,507,556.27 at the end of the previous year[11]. - The net assets attributable to shareholders increased by 2.20% to ¥5,735,527,783.99 from ¥5,611,998,691.33 at the end of the previous year[11]. - The company has a total of 206,175,000 CNY in undistributed profits as of June 30, 2022[144]. - The company’s cash management account balance was ¥1,540.00 million, contributing to a total募集资金 balance of ¥1,616.91 million[61]. Product Development - New product development includes the launch of three innovative diagnostic kits, which are expected to contribute an additional RMB 300 million in revenue by the end of 2022[6]. - The company has 93 new reagent products that have obtained registration inspection reports and have entered or completed clinical evaluation stages[33]. - The company is focusing on high-throughput and high-sensitivity diagnostic products to meet the polarized demand in hospitals[20]. - The company has installed 739 units of fully automated chemiluminescence analyzers in the domestic market during the first half of 2022, with large machine installations accounting for 61.84%, up by 13.39 percentage points year-on-year[30]. Risk Management - The management has identified key risks, including regulatory changes and market competition, and has outlined strategies to mitigate these risks in the report[2]. - The company faces risks from policy changes, particularly in the medical reform sector, which could impact operational strategies if not adjusted accordingly[71]. - The company acknowledges the impact of COVID-19 on its business, with increased demand for COVID-related testing products but a decline in regular testing services[77]. Corporate Governance - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year, opting to reinvest profits into growth initiatives[2]. - The annual shareholder meeting reported a participation rate of 59.26%, reflecting strong investor engagement[82]. - The independent director Shen Weihua resigned on May 12, 2022, leading to the election of Wu Qianhui as a new independent director on the same date[83]. Environmental and Social Responsibility - The company has implemented a series of energy-saving and carbon reduction measures, including optimizing building space design and replacing lighting with energy-efficient fixtures, contributing to a decrease in energy consumption intensity and greenhouse gas emissions[90]. - The company has engaged in various public welfare activities, including providing pandemic prevention materials and establishing the "New Industry Tree People Award" to honor outstanding educators[95]. - The company has not faced any administrative penalties related to environmental issues during the reporting period, adhering to relevant environmental laws and regulations[89].

Financial Performance - The company's revenue for Q1 2022 reached ¥742,834,914, representing a 39.53% increase compared to ¥532,371,365 in the same period last year[4]. - Net profit attributable to shareholders was ¥308,478,491, an increase of 83.46% from ¥168,144,761 in the previous year[4]. - The total profit for the same period was 358.14 million RMB, an increase of 76.23% compared to the previous year[15]. - The company achieved a revenue of 742.83 million RMB in Q1 2022, representing a year-on-year growth of 39.53%[40]. - Net profit for Q1 2022 was CNY 308,478,491.40, compared to CNY 168,144,761.01 in Q1 2021, indicating a year-over-year increase of about 83.5%[46]. Cash Flow - The net cash flow from operating activities was ¥180,613,025, up 52.03% from ¥118,803,772 in the same period last year[10]. - The net cash flow from operating activities was ¥180,613,025.70, which is an increase of approximately 52.1% from ¥118,803,772.88[48]. - The net cash flow from investing activities improved by 36.93%, with a net outflow of ¥198,467,897.58 compared to ¥314,681,230.06 in the previous year[10]. - The net cash flow from investment activities was -¥198,467,897.58, an improvement from -¥314,681,230.06 in the previous period[49]. Assets and Liabilities - The total assets at the end of the reporting period were ¥6,394,592,241.84, a 4.22% increase from ¥6,135,507,556.27 at the end of the previous year[4]. - Total liabilities decreased to ¥460,929,290.47 from ¥523,508,864.94, a reduction of approximately 11.9%[19]. - The company's equity attributable to shareholders increased to ¥5,933,662,951.37 from ¥5,611,998,691.33, representing a growth of about 5.7%[19]. - The company's total current assets amounted to CNY 4.70 billion at the end of Q1 2022, up from CNY 4.50 billion at the beginning of the year[42]. Research and Development - Research and development expenses increased by 45.33% to ¥58,500,711 from ¥40,254,361 in the same period last year, reflecting the company's commitment to innovation[9]. - R&D expenses increased to ¥58,500,711.08 from ¥40,254,361.51, representing a growth of 45.2% year-over-year[21]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 25,925[11]. - The largest shareholder, Tibet New Industry Investment Management Co., Ltd., held 26.84% of the shares, amounting to 211,177,400 shares[11]. - The company plans to lift restrictions on shares held by major shareholders on May 12, 2023, affecting a total of 518,814,829 shares[14]. Operational Metrics - The company sold and installed 1,648 automated chemiluminescence analyzers in Q1 2022, including 148 units of the MAGLUMI X8 model[15]. - The number of terminal customers served by the company's products exceeded 7,900, with 855 being top-tier hospitals, resulting in a coverage rate of 54.11%[15]. - The gross margin for the main business improved by 1.02% due to adjustments in instrument sales policies[15]. - The net profit margin improved by 9.94% year-on-year as the impact of the 2020 restricted stock incentive plan gradually diminished[40].

Financial Performance - The company's operating revenue for 2021 was ¥2,545,415,315.72, representing a 15.97% increase compared to ¥2,194,966,537.25 in 2020[12]. - The net profit attributable to shareholders for 2021 was ¥882,878,837.06, a 3.06% increase from ¥856,678,105.30 in 2020[12]. - The net cash flow from operating activities decreased by 20.83% to ¥773,218,330.43 in 2021 from ¥976,654,657.41 in 2020[12]. - The total assets at the end of 2021 were ¥6,135,507,556.27, a 15.64% increase from ¥5,305,693,720.85 at the end of 2020[12]. - The net assets attributable to shareholders increased by 16.81% to ¥5,611,998,691.33 at the end of 2021 from ¥4,804,207,896.33 at the end of 2020[12]. - The company reported a basic earnings per share of ¥1.2420 for 2021, a slight decrease of 0.77% from ¥1.2517 in 2020[12]. - The company's total revenue for the reporting period reached CNY 254,541.53 million, representing a year-on-year increase of 15.97%, and a growth of 32.22% after excluding COVID-19 related revenue[30]. - Domestic reagent sales amounted to CNY 143,328.52 million, reflecting a year-on-year growth of 26.36%, while overseas sales decreased by 18.05% to CNY 46,781.28 million[30]. - The total profit for the period was CNY 113,552.92 million, an increase of 3.53% compared to the previous year, with net profit attributable to shareholders rising by 3.68% to CNY 97,369.65 million[30]. Market and Industry Insights - The global in vitro diagnostic market was valued at $60.2 billion in 2019 and is projected to reach $84 billion by 2024, growing at a CAGR of 6.9%[17]. - The Chinese in vitro diagnostic market was approximately ¥864 billion in 2019, with a projected growth rate of 19.3% over the next five years for the immunodiagnostic segment[18]. - Domestic brands are gradually replacing imported brands in the in vitro diagnostic market, particularly in biochemical diagnostics[20]. - The domestic market for in vitro diagnostic products is rapidly growing, driven by changing healthcare consumption concepts and increasing demand due to aging and urbanization[85]. Product Development and Innovation - The company has established four major technology platforms for in vitro diagnostic product development, including nano-magnetic microspheres and fully automated diagnostic instruments[22]. - The company is focusing on high-throughput and high-sensitivity diagnostic products to meet the polarized demand in hospitals[20]. - The company is actively developing new reagent products, including those for infectious diseases and metabolic disorders, with several projects in advanced stages of development[34]. - The company has developed over 70% of key raw materials for its diagnostic reagents in-house, alleviating issues related to external procurement and high raw material costs[36]. - The company has a total of 246 patents, including 90 invention patents, which supports its innovation capabilities[45]. Sales and Distribution - The company has established a stable sales and after-sales service system both domestically and internationally, with over 10,800 units of chemiluminescence analyzers sold globally[22]. - The company sold a total of 2,884 fully automated chemiluminescence analyzers overseas in 2021, representing a year-on-year growth of 54.39%[29]. - The revenue from reagent products was approximately CNY 1.90 billion, making up 74.69% of total revenue, with a year-on-year growth of 11.50%[48]. - The revenue from instrument products was approximately CNY 638 million, accounting for 25.07% of total revenue, with a significant year-on-year increase of 31.64%[48]. Corporate Governance and Shareholder Relations - The company established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and management team since its establishment in August 2012[97]. - The board of directors has set up four specialized committees: Strategic Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee to ensure standardized operations and sustainable development[97]. - The company has a total of 12 independent directors and supervisors, ensuring a diverse governance structure[108]. - The company has ensured that minority shareholders have had sufficient opportunities to express their opinions and that their legal rights have been protected[134]. - The company has committed to strictly adhere to all public commitments made during its initial public offering and listing on the Growth Enterprise Market, actively accepting social supervision[160]. Risk Management - The company emphasizes the importance of rational investment and risk awareness in its forward-looking statements regarding future development plans[2]. - The company has detailed potential risk factors and countermeasures in its management discussion and analysis section[2]. - The company faces risks from policy changes, particularly regarding centralized procurement reforms, which could impact pricing and sales volumes[88]. - The COVID-19 pandemic has led to a surge in demand for testing products, but it has also suppressed growth in routine testing, creating uncertainty in future demand[94]. Research and Development - Research and development expenses increased by 42.81% year-on-year, amounting to ¥215,045,139.82 in 2021[57]. - The number of R&D personnel increased by 33.72% year-on-year, reaching 456 in 2021[59]. - The company is focused on developing new technologies and products to drive future growth and innovation[95]. Environmental and Social Responsibility - The company has effectively managed its environmental impact, with no administrative penalties for environmental violations during the reporting period[148]. - The company has implemented energy-saving measures, resulting in a 3.2% reduction in central air conditioning electricity consumption compared to 2020, saving 534,279 kWh[150]. - The company has actively responded to the national "3060" dual carbon goals by optimizing building space design and replacing lighting with energy-efficient fixtures[149]. Future Outlook - The company expects a revenue growth of 10% to 12% for the upcoming fiscal year, projecting revenues between 1.32 billion RMB and 1.344 billion RMB[117]. - New product launches are anticipated to contribute an additional 5% to revenue growth in 2022[117]. - The company plans to enhance its marketing efforts for biochemical instruments and reagents as it progresses with the registration of its fully automated biochemical analyzer, Biossays C8[94]. - The company intends to utilize capital market opportunities for mergers and acquisitions to achieve low-cost expansion and transformative growth[161].

Financial Performance - The company's revenue for Q3 2021 reached ¥668,175,059.80, an increase of 11.31% compared to the same period last year[4]. - Net profit attributable to shareholders was ¥237,105,891.00, reflecting a growth of 6.50% year-over-year[4]. - The net profit after deducting non-recurring gains and losses was ¥217,936,866.47, up by 6.09% from the previous year[4]. - In the first three quarters of 2021, the company achieved operating revenue of CNY 1,893.88 million, a year-on-year increase of 20.60%[16]. - The total profit for the same period was CNY 769.55 million, a decrease of 5.19% compared to the previous year[16]. - The net profit attributable to shareholders was CNY 665.72 million, down 4.67% year-on-year[16]. - The gross profit margin for the main business decreased by 7.93% year-on-year due to changes in sales policies and the impact of the COVID-19 pandemic[16]. - The company reported a comprehensive income total of CNY 665,588,597.10 for Q3 2021, compared to CNY 698,232,721.41 in the same period last year[52]. - Basic earnings per share decreased to CNY 0.8491 from CNY 0.9441 in the previous year, reflecting a decline of 10.1%[22]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥5,799,146,715.38, representing a 9.30% increase from the end of the previous year[4]. - The company's total assets reached CNY 5,799,146,715.38, up from CNY 5,305,693,720.85 at the end of 2020[51]. - The total liabilities as of the end of Q3 2021 were ¥503,959,161.18, an increase of ¥2,473,336.66 from the previous year[34]. - Total liabilities decreased to CNY 421,608,798.74 from CNY 501,485,824.52 at the end of 2020[51]. - The company's current assets totaled approximately CNY 4.29 billion, up from CNY 4.12 billion year-over-year, indicating an increase of about 4.1%[18]. - Total liabilities decreased to approximately CNY 421.61 million from CNY 501.49 million, a reduction of about 16%[19]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥450,740,954.91, down 35.08% compared to the same period last year[10]. - The net cash flow from operating activities decreased by 35.08% to ¥450,740,954.91, primarily due to increased inventory and employee compensation payments[40]. - Cash flow from operating activities was CNY 1,817,662,610.51, an increase from CNY 1,659,795,410.07 in the previous year[53]. - The net cash inflow from operating activities for Q3 2021 was CNY 450,740,954.91, a decrease of 35.1% compared to CNY 694,261,868.80 in the same period last year[24]. - The net cash outflow from investment activities was CNY -326,829,502.24, an improvement from CNY -2,480,170,073.66 in the previous year[24]. - The net cash flow from financing activities was CNY -284,474,973.01, a significant decrease from CNY 681,199,134.71 in Q3 2020[25]. Investments and Projects - The company has invested in new projects, with construction in progress reaching ¥311,838,003.21, an increase of 81.06%[8]. - The company reported a significant increase in long-term investments, with debt investments totaling CNY 100 million[18]. - The company reported a significant increase in other equity instrument investments, totaling ¥34,100,000.00, due to investments in specific funds[38]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,397[12]. - The largest shareholder, Tibet New Industry Investment Management Co., Ltd., held 26.84% of the shares, totaling 211,177,400 shares[12]. - The company has a total of 519,059,975 shares subject to restrictions, with 484,500 shares released during the reporting period[44]. Market Presence and Strategy - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[20]. - The company plans to continue expanding its market presence and product offerings in response to the evolving healthcare landscape[45]. - The company served over 7,400 domestic market end customers, with 796 being top-tier hospitals, achieving a coverage rate of 50.38%[45][16].

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, with a total revenue of RMB 1.2 billion, representing a year-on-year growth of 25%[7]. - The company has set a future revenue target of RMB 2.5 billion for the full year of 2021, indicating an expected growth rate of 20%[7]. - The company's operating revenue for the reporting period was ¥1,225,706,671.90, representing a 26.35% increase compared to ¥970,101,563.31 in the same period last year[12]. - The total revenue for the company in the first half of 2021 was 1.23 billion yuan, a 26.35% increase compared to the previous year, while the net profit attributable to shareholders decreased by 9.90% to 428.61 million yuan[31]. - The net profit attributable to shareholders was ¥428,611,762.39, a decrease of 9.90% from ¥475,729,831.60 in the previous year[12]. - The net profit after deducting non-recurring gains and losses was ¥383,099,889.21, down 12.28% from ¥436,742,159.51 year-on-year[12]. - The net cash flow from operating activities was ¥280,082,805.92, a decline of 34.03% compared to ¥424,568,683.45 in the same period last year[12]. - The company's gross profit margin for its main business decreased by 8.82% due to a reduction in instrument sales prices, although the gross margin for reagent products remained stable[31]. Market Expansion and Customer Base - User data indicates that the company has expanded its customer base, reaching over 5,000 hospitals and clinics across China, an increase of 15% compared to the previous year[7]. - The company is actively pursuing market expansion, with plans to enter Southeast Asian markets by the end of 2021, targeting a market share of 10% within the first year[7]. - The company has established a marketing network covering over 7,200 medical institutions in China, with more than 8,900 installed chemiluminescent instruments, leading the domestic market[40]. - The company has expanded its product exports to 146 countries and regions across Asia, Europe, America, Africa, and Oceania, but faces risks from import/export policies, trade barriers, and currency fluctuations[70]. Research and Development - The company has allocated RMB 200 million for research and development in 2021, focusing on innovative diagnostic technologies[7]. - The company has established four major technology platforms for the research and development of in vitro diagnostic products, focusing on continuous product and technology innovation[18]. - The company is currently developing 22 reagent products that have obtained registration inspection reports and are in the review stage by the drug regulatory authority[33]. - The company is currently developing 42 chemiluminescent reagent projects, including 26 new products and 16 second-generation products, with 22 projects under review by the drug regulatory authority[37]. - The company emphasizes the importance of new product development and has established dedicated departments to ensure timely registration and compliance with international standards[68]. - The company is committed to increasing investment in new product development to achieve a strategy of "one generation in sales, one generation in research, and one generation in reserve"[71]. Financial Position and Assets - The total assets at the end of the reporting period were ¥5,526,132,645.45, an increase of 4.15% from ¥5,305,693,720.85 at the end of the previous year[12]. - The company's cash and cash equivalents increased by ¥116,231,403.39, contrasting with a decrease of ¥242,491,819.43 in the previous year[44]. - The proportion of monetary funds to total assets rose to 21.47% from 20.25%, reflecting a stable liquidity position[47]. - The company’s total equity is implied to have increased, given the rise in total assets and the absence of significant liabilities reported[118]. Risks and Challenges - The management has identified key risks including regulatory changes and market competition, and has outlined strategies to mitigate these risks[2]. - The company faces risks related to policy changes in the medical industry, which could impact operations if not addressed[66]. - The in vitro diagnostic industry in China is experiencing intense competition, with multinational companies like Roche, Siemens, Beckman, and Abbott dominating the high-end market, particularly in tertiary hospitals[70]. - The company acknowledges the uncertainty surrounding future demand for COVID-19 testing products due to the unpredictable nature of the pandemic[72]. Shareholder and Equity Information - The company did not distribute cash dividends or bonus shares for the first half of 2021[79]. - A total of 6,078,000 restricted shares were granted to 412 incentive objects at a price of 79.57 CNY per share[79]. - The company held its annual general meeting on April 20, 2021, with a participation rate of 70.03%[77]. - The company has not experienced any changes in its board of directors, supervisors, or senior management during the reporting period[78]. - The company’s total share capital after the changes was 786,659,285 shares, representing 100% of the adjusted registered capital[103]. Environmental Compliance - The company has not received any administrative penalties related to environmental issues during the reporting period[84]. - The company effectively handles major pollutants generated during operations, including industrial wastewater and medical waste, ensuring compliance with environmental laws[84]. - The company has established effective air pollution control measures, including the collection and filtration of soldering fumes[85]. - The company’s environmental protection facilities are operating well and have passed environmental impact assessments[84]. Financial Reporting and Accounting - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance, reflecting the company's financial position as of June 30, 2021[146]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired[152]. - The company assesses expected credit losses based on the weighted average of credit losses for financial instruments, considering the risk of default[182]. - The company employs a combination of aging analysis and historical experience to determine expected credit losses for accounts receivable, with specific provisions based on aging and overall expected credit loss rates[192].

Financial Performance - The company's operating revenue for Q1 2021 was ¥532,371,365.53, representing an increase of 84.37% compared to ¥288,752,653.30 in the same period last year[4] - Net profit attributable to shareholders was ¥168,144,761.01, up 51.82% from ¥110,749,641.17 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥144,437,086.36, reflecting a 50.17% increase from ¥96,184,723.10 in the previous year[4] - Basic and diluted earnings per share were both ¥0.4078, marking a 36.39% increase from ¥0.2990 in the previous year[4] - Operating profit for Q1 2021 was ¥203,235,312.87, up 60% from ¥127,050,662.79 in the same period last year[36] - The net profit from continuing operations for Q1 2021 was ¥168,034,342.26, an increase from ¥111,331,938.70 in the same period last year, representing a growth of approximately 50.8%[39] Cash Flow - The net cash flow from operating activities reached ¥118,803,772.88, a significant increase of 346.94% compared to ¥26,581,327.43 in the same period last year[4] - Cash inflow from operating activities totaled ¥526,458,939.65, compared to ¥318,898,147.53 in the previous year, indicating a year-over-year increase of about 65.1%[41] - The net cash flow from investment activities was -¥314,681,230.06, an improvement from -¥571,524,610.27 in the same quarter last year, reflecting a reduction in losses[44] - Cash and cash equivalents at the end of the period were ¥868,885,769.24, down from ¥1,439,052,474.99 at the end of the previous year, a decrease of approximately 39.5%[42] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,502,710,368.21, an increase of 3.71% from ¥5,305,693,720.85 at the end of the previous year[4] - Total liabilities decreased to ¥459,646,418.07 from ¥501,485,824.52, a reduction of approximately 8.3%[30] - The company's total current assets reached CNY 4,273,035,019.53, up from CNY 4,124,924,367.78, indicating an increase of about 3.6%[74] - The company's equity attributable to shareholders increased to CNY 5,043,063,950.14 from CNY 4,804,207,896.33, reflecting a growth of approximately 5%[77] Research and Development - Research and development expenses increased by 45.87% to CNY 40,254,361.51, driven by increased investment in R&D during the reporting period[14] - Research and development expenses for Q1 2021 were ¥40,254,361.51, an increase of 46% from ¥27,596,275.65 in Q1 2020[35] Government Support and Subsidies - The company received government subsidies amounting to ¥9,959,220.45 during the reporting period[5] - The company received tax refunds amounting to ¥6,830,741.36, compared to ¥5,478,780.62 in the previous year, which is an increase of about 24.6%[41] Shareholder Information - The top ten shareholders held a combined 70.27% of the company's shares, with the largest shareholder owning 26.95%[7] - The top shareholder, Tibet New Industry Investment Management Co., Ltd., held 26.95% of the shares, with a total of 111,146,000 shares[53] Investment Activities - The company has committed to various investment projects, with a total of CNY 120,251,160 raised, of which CNY 72,275,030 has been utilized, indicating a progress rate of 60.14%[21] - The company plans to utilize unallocated fundraising for the "New Industry Biomedical Research and Development Building" project after terminating the unused portion of the "New Industry Biomedical Overseas Expansion Project"[22] Cost Management - The company has implemented strict cost control measures during project execution, resulting in significant savings and a remaining balance of RMB 21.93 million for the "New Industry Biomedical Research Production Base Phase II" project[22] - The company reported a significant decrease in financial expenses by 84.01%, attributed to changes in exchange gains and losses[60]